Indications for surgery in the treatment of hyperprolactinemia

Research output: Contribution to journalArticle

Abstract

Indications for pituitary surgery have been described in the medical literature, but they do not necessarily apply to prolactin-secreting (PRL- secreting) pituitary microadenomas or macroadenomas. Reviews of pituitary surgery done for microprolactinomas and macroprolactinomas have not demonstrated any significant beneficial effect on the clinical course of the hyperprolactinemia. At the same time, such surgery has been associated with definite risks, including an overall mortality of 0.9%. There is even the possibility that surgery and radiation for benign pituitary adenomas can facilitate malignant transformation and metastasis. Therefore, medical treatment with a dopamine agonist is the primary choice for all PRL-secreting microadenomas and macroadenomas. Referral for surgical evaluation is reserved for patients in whom neurologic deficits, such as visual field impairment or cranial nerve deficits, do not improve with medical therapy and for certain other, rare situations.

Original languageEnglish (US)
Pages (from-to)1127-1131
Number of pages5
JournalJournal of Reproductive Medicine for the Obstetrician and Gynecologist
Volume44
Issue number12 SUPPL.
StatePublished - 1999

Fingerprint

Hyperprolactinemia
Prolactinoma
Cranial Nerves
Vision Disorders
Dopamine Agonists
Pituitary Neoplasms
Therapeutics
Neurologic Manifestations
Visual Fields
Prolactin
Referral and Consultation
Radiation
Neoplasm Metastasis
Mortality

Keywords

  • Dopamine agonists
  • Hypophysectomy
  • Pituitary neoplasms
  • Prolactinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Indications for surgery in the treatment of hyperprolactinemia. / Zacur, Howard A.

In: Journal of Reproductive Medicine for the Obstetrician and Gynecologist, Vol. 44, No. 12 SUPPL., 1999, p. 1127-1131.

Research output: Contribution to journalArticle

@article{94097c6ce1084e55b0c97f59329dcf15,
title = "Indications for surgery in the treatment of hyperprolactinemia",
abstract = "Indications for pituitary surgery have been described in the medical literature, but they do not necessarily apply to prolactin-secreting (PRL- secreting) pituitary microadenomas or macroadenomas. Reviews of pituitary surgery done for microprolactinomas and macroprolactinomas have not demonstrated any significant beneficial effect on the clinical course of the hyperprolactinemia. At the same time, such surgery has been associated with definite risks, including an overall mortality of 0.9{\%}. There is even the possibility that surgery and radiation for benign pituitary adenomas can facilitate malignant transformation and metastasis. Therefore, medical treatment with a dopamine agonist is the primary choice for all PRL-secreting microadenomas and macroadenomas. Referral for surgical evaluation is reserved for patients in whom neurologic deficits, such as visual field impairment or cranial nerve deficits, do not improve with medical therapy and for certain other, rare situations.",
keywords = "Dopamine agonists, Hypophysectomy, Pituitary neoplasms, Prolactinoma",
author = "Zacur, {Howard A}",
year = "1999",
language = "English (US)",
volume = "44",
pages = "1127--1131",
journal = "The Journal of reproductive medicine",
issn = "0024-7758",
publisher = "Donna Kessel",
number = "12 SUPPL.",

}

TY - JOUR

T1 - Indications for surgery in the treatment of hyperprolactinemia

AU - Zacur, Howard A

PY - 1999

Y1 - 1999

N2 - Indications for pituitary surgery have been described in the medical literature, but they do not necessarily apply to prolactin-secreting (PRL- secreting) pituitary microadenomas or macroadenomas. Reviews of pituitary surgery done for microprolactinomas and macroprolactinomas have not demonstrated any significant beneficial effect on the clinical course of the hyperprolactinemia. At the same time, such surgery has been associated with definite risks, including an overall mortality of 0.9%. There is even the possibility that surgery and radiation for benign pituitary adenomas can facilitate malignant transformation and metastasis. Therefore, medical treatment with a dopamine agonist is the primary choice for all PRL-secreting microadenomas and macroadenomas. Referral for surgical evaluation is reserved for patients in whom neurologic deficits, such as visual field impairment or cranial nerve deficits, do not improve with medical therapy and for certain other, rare situations.

AB - Indications for pituitary surgery have been described in the medical literature, but they do not necessarily apply to prolactin-secreting (PRL- secreting) pituitary microadenomas or macroadenomas. Reviews of pituitary surgery done for microprolactinomas and macroprolactinomas have not demonstrated any significant beneficial effect on the clinical course of the hyperprolactinemia. At the same time, such surgery has been associated with definite risks, including an overall mortality of 0.9%. There is even the possibility that surgery and radiation for benign pituitary adenomas can facilitate malignant transformation and metastasis. Therefore, medical treatment with a dopamine agonist is the primary choice for all PRL-secreting microadenomas and macroadenomas. Referral for surgical evaluation is reserved for patients in whom neurologic deficits, such as visual field impairment or cranial nerve deficits, do not improve with medical therapy and for certain other, rare situations.

KW - Dopamine agonists

KW - Hypophysectomy

KW - Pituitary neoplasms

KW - Prolactinoma

UR - http://www.scopus.com/inward/record.url?scp=0033427587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033427587&partnerID=8YFLogxK

M3 - Article

C2 - 10649823

AN - SCOPUS:0033427587

VL - 44

SP - 1127

EP - 1131

JO - The Journal of reproductive medicine

JF - The Journal of reproductive medicine

SN - 0024-7758

IS - 12 SUPPL.

ER -